Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지

Optimal Sampling Times of Once Daily Gentamicin in Korean Patients with Urinary Tract Infections

  • Park, Hyo-Jung (Division of Pharmaceutical Services, Samsung Medical Center) ;
  • Sohn, Kie-Ho (Division of Pharmaceutical Services, Samsung Medical Center) ;
  • Choi, Kyung-Eob (Division of Infectious Diseases, Samsung Medical Center, SungKyunKwan University School of Medicine) ;
  • Shin, Sang-Yup (Division of Infectious Diseases, Samsung Medical Center, SungKyunKwan University School of Medicine) ;
  • Jung, Sook-In (Division of Infectious Diseases, Samsung Medical Center, SungKyunKwan University School of Medicine) ;
  • Oh, Won-Sup (Division of Infectious Diseases, Samsung Medical Center, SungKyunKwan University School of Medicine) ;
  • Peck, Kyong-Ran (Division of Infectious Diseases, Samsung Medical Center, SungKyunKwan University School of Medicine) ;
  • Song, Jae-Hoon (Division of Infectious Diseases, Samsung Medical Center, SungKyunKwan University School of Medicine) ;
  • Lee, Suk-Hyang (Collage of Pharmacy, Sookmyung Womens University)
  • Published : 2003.09.01
Download PDF
⟨ Previous Next ⟩

Abstract

The clinical use of once daily aminoglycoside (ODA) dosing has been increased because of the potential therapeutic advantages of this dosing regimen. To evaluate the optimal sampling times of ODA dosing method in a clinical setting, the study was prospectively conducted in a total of 28 patients with UTI. All of the patients were intravenously administered gentamicin at a dose of 7 mg/kg over 60 minutes and randomly divided into two groups. Blood was collected at 0, 2, and 6 hours in Group A and at 1, 2, and 6 hours in Group B after the end of 1-hour infusion. The pharmacokinetic parameters (Ke, Vd and Cmax) obtained using the 0, 6 hour levels and 2, 6 hour levels in Group A were statistically different while those of 1, 6 hour levels and 2, 6 hour levels in Group B were similar. This finding indicated that the distributional phase of ODA is completed within 1 hour following the end of the I-hour infusion. If we are allowed to collect only two blood samples in ODA considering patients comfort and the analytical cost of drug, the first one should be drawn after 1 hour following the end of infusion to obtain adequate pharmacokinetic information.

Keywords

References

  1. Aminimanizani, A., Beringer, P. M., Kang, J. et at. (2002). Distibution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. J. Antimicrob. Chemother. 50, 553-559 https://doi.org/10.1093/jac/dkf168
  2. Barclay, M. L., Begg, E. J., and Hickling, K. G. (1994). What is the evidence for once-daily aminoglycoside therapy? Clin. Pharmacokinet. 27, 32-48 https://doi.org/10.2165/00003088-199427010-00004
  3. Barclay, M. L., Kirkpatrick, C. M. J., and Begg, E. J. (1999). Once daily arninoglycaside therapy. Is it less toxic than multiple daily doses and how should it be monitored? Clin. Pharmacokinet. 36, 89-98 https://doi.org/10.2165/00003088-199936020-00001
  4. Bartal, c., Danon, A., Schlaeffer E, et at. (2003). Pharmacokinetic dosing aminoglycosides: a controlled triaL Am. J. Med. 114, 194-198 https://doi.org/10.1016/S0002-9343(02)01476-6
  5. Bates, R. D. and Nahata M. C. (1994). Once daily administration of aminoglycosides. Ann. Pharamcother. 28, 757-766 https://doi.org/10.1177/106002809402800614
  6. Buijk, S. E., Mouton, J. W., Gyssens, I. C., et al. (2002). Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med. 28, 936-42 https://doi.org/10.1007/s00134-002-1313-7
  7. Chuck, S. K., Raber, S. R., Rodvold, K. A., et al. (2000). National survey of extended-interval aminoglycosde dosing. Clin. Infect. Dis. 30, 433-439 https://doi.org/10.1086/313692
  8. Demczar 1. Do, Nafziger A. N., and Bertino J. S. Jr. (1997). Phar macokinetics of gentamicin at traditional versus high dose Implications for once daily aminoglycoside dosing. Antimicrobial Agents. Chemother. 41, 1115-1119
  9. Fantin, ~., Ebert, S., Leggett, J., et aL (1990). Factors affecting duration of lll-VIVO postantibiotic effect for aminoglycosides against gram-negative bacilli. J. Antimicrob. Chemother: 27 829-836 https://doi.org/10.1093/jac/27.6.829
  10. Freeman, C. D.. Nicolau, D. P., Belliveau, P. P., et al. (1997). Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J. Antimicrob. Chemother. 39 677-686 https://doi.org/10.1093/jac/39.6.677
  11. Lacy, M. K., Nicolau, D. P., Nightingale, C. H., et aL (1998). The pharmacodynamics of aminoglycosides, Clin. Infect. Dis. 27, 23-27 https://doi.org/10.1086/514620
  12. Moore, R. D., Lietrnan, P. S., and Smith, C. R. (1987). Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis. 155, 93-99 https://doi.org/10.1093/infdis/155.1.93
  13. Morris, R. G., Sallustio, B. C., Vinks, A. A., et al. (1999). Some international approaches to aminoglycoside monitoring in the extended dosing interval era. Ther. Drug Monit. 21, 379-388 https://doi.org/10.1097/00007691-199908000-00001
  14. Nicolau, D. P., Freeman, C. D., Belliveau, P. P. et al. (1995). Experience with a once daily aminoglycoside pgogram administered to 2,183 adult patients. Antimicrobial Agents. Chemother. 39, 650-655
  15. Preston, S. L. and Briceland, L. L. (1995). Single daily dosing of aminoglycosides. Pharmacotherapy 15, 297-316
  16. Rotschasfer, J. C. and Rybak, M. J. (1994). Single daily dosing of aminoglycosides: a commentary. Ann. Pharmacother. 28, 797-801 https://doi.org/10.1177/106002809402800618
  17. Paterson, D. L., Robson, J. M., Wagener, M. M., et al (1999). Monitoring of serum aminoglycoside levels with once-daily dosing. Pathology. 31, 289-294
  18. Zaske D. E., Evans w., Schentag J. J., and Jusko W. 1. (1992). Applied Pharmacokinetics. 3rd ed. Applied Therapeutics
  19. Zhanel, G. G. and Craig, W. A. (1994). Pharmacokinetic contributions to postantibiotic effects. Clin. Pharmacokinet. 27 377- 392 https://doi.org/10.2165/00003088-199427050-00005
  20. Van Der Auwera P. (1991). Pharmacokinetic evaluation of single daily dose amikacin. J. Antimicrob. Chemother. 27, 63-71 https://doi.org/10.1093/jac/27.1.63
  21. Wallace, A. w., Jones, M. 1., Bertino, J. S. Jr. (2002). Evaluation of four once daily arninoglycoside dosing nomograms. Pharmacotherapy 22, 1077-1083 https://doi.org/10.1592/phco.22.13.1077.33529
  22. Wenk M., Spring P., Vozeh S., et a1. (1979). Multicompartment pharmacokinetics of netilmicin. Eur: J. Clin. Pharmacol. 16 331-334 https://doi.org/10.1007/BF00605631